Werkgroep Cardiologische centra Nederland

VICTORIA (Follow-up)

A randomized parallel-group, placebo-controlled, double-blind, event-driven, multicenter pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator vericiguat (BAY 1021189) in patients with heart failure and reduced ejection fraction (HFrEF) - VerICiguaT glObal study in patients with HF and Reduced ejectIon frAction (VICTORIA)
Medicine
Vericiguat
Population
Heart failure
Phase
III
Starting year
2016
More information
ClinicalTrials.gov